Answers are grounded in this paper and cite their sources.
MMP-2 has long been a drug target. The current status of MMP-2 inhibitors as anticancer agents and their failure in the clinic is discussed in light of new data on the MMP-2s role as a cell surface transducer - data that may lead to the design and development of novel, MMP-2-targeting inhibitors.
No takes yet. Share an insight, caveat, or question.
Chien et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: